MedTrace Logo

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

NCT05891171 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-31

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Conditions

Interventions

DRUG

AB598

Administered as specified in the treatment arm

DRUG

Zimberelimab

Administered as specified in the treatment arm

DRUG

Fluorouracil

Administered as specified in the treatment arm

DRUG

Leucovorin

Administered as specified in the treatment arm

DRUG

Oxaliplatin

Administered as specified in the treatment arm

Sponsors & Collaborators

  • Arcus Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Arcus Biosciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-13
Primary Completion
2026-03-31
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891171 on ClinicalTrials.gov